

Cancer **I**mmunology **I**mmunotherapy

Founding Editor
G. Mathé

Other Biological Response Modifications

Volume 34 1991/92

Editors in Chief

R. W. Baldwin E. Mihich

Editorial Board

F. Balkwill London

J. Bennett Albany, NY

N. Bloksma Utrecht

H. Blythman Basel

R. Bolhuis Rotterdam

V. S. Byers Nottingham

T. Carey Ann Arbor, MI

M. Cheever Seattle, WA

M. Colnaghi Milan

S. Dray Chicago, IL

S. Eccles Sutton, Surrey

M. J. Ehrke Buffalo, NY

M. Fopp St. Gallen

E. Grimm Houston, TX

K. Hellström Seattle, WA

K. Höfken Essen

A. Houghton New York, NY

H. Kirchner Heidelberg

E. Kleinerman Houston, TX

W. Knapp Vienna

H. Kobayashi Sapporo

M. Mastrangelo Philadelphia, PA

J. McVie London

M. Mitchell Los Angeles, CA

M. Moore London

R. J. North Saranac Lake, NY

G. Parmiani Milan

M. Price Nottingham

R. Rees Sheffield

R. A. Reisfeld La Jolla, CA

H. F. Sewell Nottingham

K. Sikora London

Z. Steplewski Philadelphia, PA

G. Stevenson Southampton

J. Talmadge Omaha, NE

E. Tsubura Osaka

A. Uchida Kyoto

F. Vánky Stockholm

E. Vitetta Dallas, TX

B. Vose Cheshire



Springer International

Cancer Immunology Immunotherapy

Other Biological Response Modifications

This journal was founded in 1976. Founding editor: G. Mathé

Editors: R. W. Baldwin, E. Mihich

Published by Springer International

Copyright

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.

All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e. g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Special regulations for photocopies in the USA: Photocopies may be made for personal or inhouse use beyond the limitations stipulated under Section 107 or 108 of U. S. Copyright Law, provided a fee is paid. This fee is US \$ 0.20 per page per copy, plus a basic fee of US \$ 2.00 per article. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0340-7004, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

Printed in Germany by E. Kieser GmbH Graphischer Betrieb, D-8902 Neusäß bei Augsburg

© Springer-Verlag Berlin Heidelberg 1992

Contents of volume 34

No. 1 (pp 1-70) published October 1991
 No. 2 (pp 71-142) published November 1991
 No. 3 (pp 143-210) published December 1991
 No. 4 (pp 211-282) published January 1992
 No. 5 (pp 283-354) published February 1992
 No. 6 (pp 355-426) published March 1992

Aarden LA → De Boer EC

Acerbis G, Cleris L, Rodolfo M, Parmiani G, Formelli F: Postsurgical adjuvant chemoinmunotherapy with recombinant interleukin-2 and 1,3-bis-(2-chloroethyl)-1-nitrosourea on spontaneous metastases of a non-immunogenic murine tumour 383

Adachi K, Belser P, Bender H, Li D, Rodeck U, Benveniste EN, Woo D, Schmiegel WH, Herlyn D: Enhancement of epidermal growth factor receptor expression on glioma cells by recombinant tumor necrosis factor α 370

Advani S → Jhaver K

Advani SH → Damle RN

Altemeyer A → Palisson M-J

Ambinder EP → Richner J

Anderer FA → Doelker I

Anderson PM → Katsanis E

Arienti F → Rivoltini L

Arnold B → Vlock DR

Arzano S → Liberati AM

Asano T → Tsuchiya Y

Avila-Cariño J, Torsteinsdottir S, Ehlin-Henriksson B, Masucci MG, Klein E: Search for the critical characteristics of phenotypically different B cell lines, Burkitt lymphoma cells and lymphoblastoid cell lines, which determine differences in their functional interaction with allogeneic lymphocytes 128

Baker SR → Vlock DR

Bareford D → Lim SH

Bartik MM, Baumgartel-Scofield BA, Mokyr MB: Enhanced expansion of the thymic CD8⁺ cell subset as a potential mechanism for the generation of enhanced antitumor cytotoxicity by thymocytes from low-dose melphalan-treated MOPC-315 tumor bearers 79

Basse P, Herberman RB, Hokland M, Goldfarb RH: Tissue distribution of adoptively transferred adherent lymphokine-activated killer cells assessed by different cell labels 221

Bassi C → Rodolfo M

Baumgartel-Scofield BA → Bartik MM

Bausero MA → Katsanis E

Beelen DW, Grosse-Wilde H, Ryschka U, Quabeck K, Sayer HG, Graeven U, Schaefer UW: Initial treatment of acute graft-versus-host disease with a murine monoclonal antibody directed to the human $\alpha\beta$ T cell receptor 97

Beelen RHJ → Loosdrecht AA van de

Bekesi G → Richner J

Bell A → Lim SH

Bellgrau D → Redd JM

Belser P → Adachi K

Ben-Efraim S → Farkas R

Bender H → Adachi K

Benjamin R → Kleinerman ES

Benveniste EN → Adachi K

Berczi I → Nagy E

Bergenbrant S → Österborg A

Bergers JJ, Den Otter W, De Groot JW, De

Blois AW, Dullens HFJ, Steerenberg PA, Crommelin DJA: Reconstituted membranes of tumour cells (proteoliposomes) induce specific protection to murine lymphoma cells 233

Berruto P → Liberati AM

Bianco AR → Correale P

Bigler RD → Hubbel HR

Bischoff P → Palisson M-J

Blair AH → Ghose T

Blaney BAD → Hasan SI

Blazar BR → Katsanis E

Bolhuis RLH, Sturm E, Braakman E: T cell targeting in cancer therapy 1

Bonavida B → Safrit JT

Borrebaeck CAK → Janssen B

Bottari V → Sanctis G de

Boven E → Haisma HJ

Boven E → Molthoff CFM

Braakhuis BJM → Schrijvers AHGJ

Braakman E → Bolhuis RLH

Broekhoven MG → Loosdrecht AA van de

Bucana CD → Kleinerman ES

Burger R → Steerenberg PA

Caraglia M → Correale P

Carey TE → Vlock DR

Casellas P → Rostain-Capaillon O

Cefalo G → Rivoltini L

Celio L → Correale P

Centis F → Pellegrini R

Cheung L → Mujoo K

Cinieri S → Liberati AM

Cleris L → Acerbis G

Cohen EP → Kim YS

Cohen SA → Tzong S-P

Colnaghi MI → Pellegrini R

Coppola V → Correale P

Correale P, Procopio A, Celio L, Caraglia M, Genua G, Coppola V, Pepe S, Normanno N, Vecchio I, Palmieri G, Montagnani S, Tagliaferri P, Bianco AR: Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer- and lymphokine-activated-killer-mediated cytotoxicity 272

Cox DC → Farone AL

Crommelin DJA → Bergers JJ

Damle RN, Advani SH, Gangal SG: Impairment in proliferation, lymphokine production and frequency distribution of mitogen-responsive and interleukin-2-producing cells in Hodgkin's disease 205

De A → Jhaver K

De Blois AW → Bergers JJ

De Boer EC, De Jong WH, Steerenberg PA, Aarden LA, Tetteroo E, De Groot ER, Van der Meijden APM, Vegt PDJ, Debruyne FMJ, Ruitenberg EJ: Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer 306

De Groot ER → De Boer EC

De Groot JW → Bergers JJ

De Jong WAC → Rutten VPMG

De Jong WH → De Boer EC

De Jong WH → Rutten VPMG

De Jong WH → Steerenberg PA

De Vries R → Haisma HJ

Dean G → Spicer DV

Debruyne FMJ → De Boer EC

Den Otter W → Bergers JJ

Den Otter W → Rutten VPMG

Den Otter W → Steerenberg PA

Di Clemente F → Liberati AM

Digel W, Zahn G, Heinzel G, Porzolt F: Pharmacokinetics and biological activity in subcutaneous long-term administration of recombinant interferon- γ in cancer patients 169

Doelker I, Anderer FA: The CySF-L2 factor from dialysable human leucocyte extract activates natural killer cytotoxicity by induction of interferon γ 299

Dongen GAMS van → Schrijvers AHGJ

Dullens HFJ → Bergers JJ

Economou JS, Hoban M, Lee JD, Essner R, Swisher S, McBride W, Hoon DB, Morton DL: Production of tumor necrosis factor α and interferon γ in interleukin-2-treated melanoma patients: correlation with clinical toxicity 49

Ehlin-Henriksson B → Avila-Cariño J

Einat E → Yefenof E

Epenetos AA → Maraveyas A

Essner R → Economou JS

Farkas R, Ben-Efraim S, Manor Y, Zan-Bar I, Klajman A: Appearance of the T-cell marker CD8 on B chronic lymphatic leukemia cells in long-term cultures 181

Farone AL, Cox DC: 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)/interleukin-2 chemoinmunotherapy of murine L 1210 leukemia 279

Ferrone S → Ghose T

Feuer EJ → Richner J

Ficcardi M → Sanctis G de

Fidler IJ → Kleinerman ES

Filippo S → Liberati AM

Finch MD → Tsang KY

Fizzotti M → Liberati AM

Fontana L → Sanctis G de

Formelli F → Acerbis G

Fossati-Bellani F → Rivoltini L

Frezzolini A → Sanctis G de

Gambacorti-Passerini C → Rivoltini L

Gangal SG → Damle RN

Gasparini M → Rivoltini L

Geerse E → Steerenberg PA

Geertsens PF → Hermann GG

Genua G → Correale P

Gerretsen M → Schrijvers AHGJ

Ghose T, Ferrone S, Blair AH, Kralovec Y,

Temponi M, Singh M, Mammen M: Regres-

- sion of human melanoma xenografts in nude mice injected with methotrexate linked to monoclonal antibody 225.28 to human high molecular weight melanoma associated antigen 90
- Gibson GD → Hubbel HR
 Glennie M → Greenman J
 Goldfarb RH → Basse P
 Goldstone AH → Lim SH
 Gopas J, Itzhaky D, Segev Y, Salzberg S, Trink B, Isakov N: Persistent measles virus infection enhances major histocompatibility complex class I expression and immunogenicity of murine neuroblastoma cells 313
- Gozzard D → Lim SH
 Graeven U → Beelen DW
 Greenman J, Hogg N, Nikolett S, Slade C, Stevenson G, Glennie M: Comparative efficiencies of bispecific F(ab')₂ and chimeric mouse/human IgG antibodies in recruiting cellular effectors for cytotoxicity via Fcγ receptors 361
- Grosse-Wilde H → Beelen DW
 Gupta RK → Hunt KK
- Haimovich J → Taya M
 Haisma HJ, Boven E, Muijen M van, De Vries R, Pinedo HM: Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphate 343
- Harris MB → Kleinerman ES
 Hasan SI, Blaney BAD, Turk JL: Effect of anticancer drugs on the release of interleukin-6 in vitro 228
- Hauptmann G → Palisson M-J
 Hayahara N → Ikemoto S
 Hayashi Y, Hoon DSB, Park MS, Terasaki PI, Morton DL: Cytotoxic T cell lines recognize autologous and allogeneic melanomas with shared or cross-reactive HLA-A 419
- Heinzel G → Digel W
 Herberman RB → Basse P
 Herlyn D → Adachi K
 Herman R → Spicer DV
 Hermann GG, Geertsen PF, Maase H von der, Zeuthen J: Interleukin-2 dose, blood monocyte and CD25⁺ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma 111
- Hoban M → Economou JS
 Hoffmann K → Richner J
 Hogg N → Greenman J
 Hokland M → Basse P
 Holm G → Österborg A
 Hoon DB → Economou JS
 Hoon DSB → Hayashi Y
 Horisberger M → Liberati AM
 Hozawa S → Yamakido M
 Hubbell HR, Gibson GD, Bigler RD: Potentiated lymphokine-activated killer cell activity generated by low-dose interleukin-2 and mismatched double-stranded RNA 259
- Humpierrez J → Vlock DR
 Hunt KK, Shibata M, Gupta RK, Morton DL: Complement-dependent lysis of tumor cells by a baboon IgM antibody to a tumor-associated antigen 377
- Ikemoto S, Wada S, Kamizuru M, Hayahara N, Kishimoto T, Maekawa M: Clinical studies on cell-mediated immunity in patients with renal cell carcinoma: interleukin-2 and interferon-γ production of lymphocytes 289
- Inoue M → Tsuchiya Y
 Isakov N → Gopas J
 Ishioka S → Yamakido M
 Itzhaky D → Gopas J
- Jaffe N → Kleinerman ES
 Jansson B, Borrebaeck CAK: The human repertoire of antibody specificities against Thomsen-Friedenreich and Tn-carcinoma-associated antigens as defined by human monoclonal antibodies 294
- Jhaver K, De A, Advani S, Nadkarni J: Production of interleukin-1 and tumour necrosis factor in non-Hodgkin's lymphoma patients 123
- Kamizuru M → Ikemoto S
 Katsanis E, Bausero MA, Ochoa AC, Loeffler CM, Blazar BR, Leonard AS, Anderson PM: Importance in timing of cyclophosphamide on the enhancement of interleukin-2-induced cytotoxicity 74
- Kelley A → Spicer DV
 Kelsey S → Lim SH
 Kleinerman ES, Raymond AK, Bucana CD, Jaffe N, Harris MB, Krakoff IH, Benjamin R, Fidler IJ: Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835 A lipid) 211
- Kim YS, Slomski R, Cohen EP: Immunity to melanoma in mice immunized with transfected allogeneic mouse fibroblasts expressing melanoma-associated antigens 163
- Kishimoto T → Ikemoto S
 Klajman A → Farkas R
 Klein E → Avila-Carriño J
 Klein E → Yefenof E
 Klein WR → Rutten VPMG
 Klein-Struckmeier A, Knüver-Hopf J, Mohr H: Modulation of natural and interleukin-2-induced tumour-cytolytic activities by the members of a protein family related to β-thromboglobulin 175
- Knüver-Hopf J → Klein-Struckmeier A
 Krakoff IH → Kleinerman ES
 Kralovec Y → Ghose T
 Krause CJ → Vlock DR
 Kruse CA → Redd JM
 Kumar P → Wright SC
 Kuramoto E, Yano O, Shimada S: Induction of T-cell-mediated immunity against MethA fibrosarcoma by intratumoral injections of a bacillus Calmette-Guérin nucleic acid fraction 283
- Lagarde A-C → Redd JM
 Langenhuijsen MMAC → Loosdrecht AA van de
 Lee JD → Economou JS
 Lefvert A-K → Österborg A
 Leonard AS → Katsanis E
 Leung KH: Human lymphokine-activated killer (LAK) cells. III. Effect of L-phenylalanine methyl ester on LAK cell activation from human peripheral blood mononuclear cells: possible protease involvement of monocytes, natural killer cells and LAK cells 31
- Li D → Adachi K
 Liberati AM, Horisberger M, Schippa M, Di Clemente F, Fizzotti M, Filippo S, Proietti MG, Arzano S, Berruto P, Palmisano L, Cinieri S: Biochemical and immunological responses of hairy cell leukemia patients to interferon β 115
- Lim SH, Newland AC, Kelsey S, Bell A, Offerman E, Rist C, Gozzard D, Bareford D, Smith MP, Goldstone AH: Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia - a phase II study 337
- Loeffler CM → Katsanis E
 Loosdrecht AA van de, Ossenkoppele GJ, Beelen RHJ, Broekhoven MG, Langenhuijsen MMAC: Role of interferon γ and tumour necrosis factor α in monocyte-mediated cytotoxicity and cytotoxicity against a human histiocytic lymphoma cell line 393
- Maase H von der → Hermann GG
 Maekawa M → Ikemoto S
 Mammen M → Ghose T
 Mandelli F → Sanctis G de
 Manor Y → Farkas R
 Maraveyas A, Epenetos AA: An overview of radioimmunotherapy 71
- Martignone S → Pellegrini R
 Mastroianni A → Pellegrini R
 Masucci M → Österborg A
 Masucci MG → Avila-Carriño J
 Matsutani M → Tsuchiya Y
 Matsuzaka S → Yamakido M
 McBride W → Economou JS
 Mellstedt H → Österborg A
 Ménard S → Pellegrini R
 Misdorp W → Rutten VPMG
 Mitchell MS → Spicer DV
 Mohr H → Klein-Struckmeier A
 Mokyr MB → Bartik MM
 Moltzoff CFM, Pinedo HM, Schlüper HMM, Boven E: Pharmacokinetics and biodistribution of a new anti-episialin monoclonal antibody 139H2 in ovarian-cancer-bearing nude mice 191
- Montagnani S → Correale P
 Moosbrugger I → Palisson M-J
 Morton DL → Economou JS
 Morton DL → Hayashi Y
 Morton DL → Hunt KK
 Morton H → Quinn KA
 Muijen M van → Haisma HJ
 Mujoo K, Reisfeld RA, Cheung L, Rosenblum MG: A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD₂ 198
- Nadkarni J → Jhaver K
 Nagy E, Berci I, Sehon AH: Growth inhibition of murine mammary carcinoma by monoclonal IgE antibodies specific for the mammary tumor virus 63
- Newland AC → Lim SH
 Nikolett S → Greenman J
 Nishimoto Y → Yamakido M
 Normanno N → Correale P
- Ochoa AC → Katsanis E
 Offerman E → Lim SH
 Orazi A → Rivoltini L
 Ossenkoppele GJ → Loosdrecht AA van de

Ikemoto S, Wada S, Kamizuru M, Hayahara N, Kishimoto T, Maekawa M: Clinical studies

- Österberg A, Masucci M, Bergenbrant S, Holm G, Lefvert A-K, Mellstedt H: Generation of T cell clones binding F(ab')₂ fragments of the idiotype immunoglobulin in patients with monoclonal gammopathy 157
- Otake M → Yamakido M
- Palisson M-J, Altemeyer A, Moosbrugger I, Warter S, Hauptmann G, Bischoff P: Anti-(human LFA-1) monoclonal antibodies bind P815 murine tumour cells 407
- Palmieri G → Correale P
- Palmisano L → Liberati AM
- Park MS → Hayashi Y
- Parmiani G → Acerbis G
- Parmiani G → Rivoltini L
- Parmiani G → Rodolfo M
- Parry HJ, Rees RC: Differential effects of human blood monocytes on the growth of human tumour cell lines in vitro 355
- Pellegrini R, Centis F, Martignone S, Mastroianni A, Tagliabue E, Tosi E, Ménard S, Colnaghi MI: Characterization of a monoclonal antibody directed against the epidermal growth factor receptor binding site 37
- Pepe S → Correale P
- Petti MC → Sanctis G de
- Pinedo HM → Haisma HJ
- Pinedo HM → Molthoff CFM
- Porzolt F → Digel W
- Primus FJ → Tsang KY
- Procopio A → Correale P
- Proietti MG → Liberati AM
- Quabeck K → Beelen DW
- Quak JJ → Schrijvers AHGJ
- Quinn KA, Morton H: Effect of monoclonal antibodies to early pregnancy factor (EPF) on the in vivo growth of transplantable murine tumours 265
- Raymond AK → Kleiner ES
- Redd JM, Lagarde A-C, Kruse CA, Bellgrau D: Allogeneic tumour-specific cytotoxic T lymphocytes 349
- Rees RC → Parry HJ
- Reisfeld RA → Mujoo K
- Richner J, Ambinder EP, Hoffmann K, Feuer EJ, Bekesi G: Number of helper T cells and phytohemagglutinin stimulation correlate in cancer patients 138
- Rist C → Lim SH
- Rivoltini L, Arienti F, Orazi A, Cefalo G, Gasparini M, Gambacorti-Passerini C, Fossati-Bellani F, Parmiani G: Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype 241
- Rodeck U → Adachi K
- Rodolfo M, Bassi C, Salvi C, Parmiani G: Therapeutic use of a long-term cytotoxic T cell line recognizing a common tumour-associated antigen: the pattern of in vitro reactivity predicts the in vivo effect on different tumours 53
- Rodolfo M → Acerbis G
- Rosenblum MG → Mujoo K
- Rossi G de → Sanctis G de
- Rostaing-Capillon O, Casellas P: In vivo cytotoxic efficacy of immunotoxins prepared from anti-CD5 antibody linked to ricin A-chain 24
- Ruitenbergh EJ → De Boer EC
- Ruitenbergh EJ → Rutten VPMG
- Rutten VPMG, Klein WR, De Jong WAC, Misdorp W, Steerenberg PA, De Jong WH, Den Otter W, Ruitenbergh EJ: Immunotherapy of bovine ocular squamous cell carcinoma by repeated intralesional injections of live bacillus Calmette-Guérin (BCG) or BCG cell walls 186
- Ryoyama C → Ryoyama K
- Ryoyama K, Ryoyama C: Cyclophosphamide modifies the induction kinetics but not cell types and cytotoxic mechanisms of anti-tumour cells elicited with OK-432 plus attenuated tumor cells 143
- Ryschka U → Beelen DW
- Safrit JT, Bonavida B: Hierarchy of in vitro sensitivity and resistance of tumor cells to cytotoxic effector cells, cytokines, drugs and toxins 321
- Salvi C → Rodolfo M
- Salzberg S → Gopas J
- Sanctis G de, Bottari V, Frezzolini A, Ficcardi M, Rossi G de, Petti MC, Mandelli F, Fontana L: Ability of recombinant interferon γ in vitro to restore the defective polymorphonuclear-cell-but not lymphocyte-mediated cytotoxic activities in patients with myelodysplastic syndromes 414
- Sato S → Tsuchiya Y
- Sayer HG → Beelen DW
- Schaefer UW → Beelen DW
- Scheper RJ → Steerenberg PA
- Schipa M → Liberati AM
- Schlom J → Tsang KY
- Schlüper HMM → Molthoff CFM
- Schmiegel WH → Adachi K
- Schrijvers AHGJ, Gerretsen M, Walsum M van, Braakhuysen BJM, Quak JJ, Snow GB, Dongen GAMS van: Potential for targeting head and neck squamous cell carcinoma with monoclonal antibody K984 252
- Schwartz DR → Vlock DR
- Segev Y → Gopas J
- Sehon AH → Nagy E
- Shibata M → Hunt KK
- Shigenobu T → Yamakido M
- Shimada S → Kuramoto E
- Singh M → Ghose T
- Slade C → Greenman J
- Slomski R → Kim YS
- Smith MP → Lim SH
- Snow GB → Schrijvers AHGJ
- Spicer DV, Kelley A, Herman R, Dean G, Stevenson L, Mitchell MS: Low-dose recombinant interleukin-2 and low-dose cyclophosphamide in metastatic breast cancer 424
- Steerenberg PA, Geerse E, De Jong WH, Burger R, Scheper RJ, Den Otter W: Tumour rejection after adoptive transfer of line-10-immune spleen cells is mediated by two T cell subpopulations 103
- Steerenberg PA → Bergers JJ
- Steerenberg PA → De Boer EC
- Steerenberg PA → Rutten VPMG
- Stevenson G → Greenman J
- Stevenson L → Spicer DV
- Sturm E → Bolhuis RLH
- Swanson N → Vlock DR
- Swisher S → Economou JS
- Tagliabue E → Pellegrini R
- Tagliaferri P → Correale P
- Tam AW → Wright SC
- Taya M, Haimovich J: Immunotherapy of B lymphoma by anti-idiotypic antibodies: characterization of variant tumour cells appearing a long time after the initial tumour inoculation 43
- Temponi M → Ghose T
- Terasaki PI → Hayashi Y
- Tetteroo E → De Boer EC
- Torsteinsdottir S → Avila-Cariño J
- Tosi E → Pellegrini R
- Trink B → Gopas J
- Tsang KY, Finch MD, Primus FJ, Schlom J: Human recombinant interleukin-6 enhances antibody-dependent cellular cytotoxicity of human tumor cells mediated by human peripheral blood mononuclear cells 9
- Tsuchiya Y, Matsutani M, Inoue M, Sato S, Asano T, Yajima M: Effect of a glucan, sizofiran, on natural-killer activity of 5-fluorouracil-treated murine bone marrow cells 17
- Türk JL → Hasan SI
- Tzung S-P, Cohen SA: Endogenous interferon α/β produced by Kupffer cells inhibits interleukin-1, tumor necrosis factor α production and interleukin-2-induced activation of nonparenchymal liver cells 150
- Van der Meijden APM → De Boer EC
- Vecchio I → Correale P
- Vegt PDJ → De Boer EC
- Vlock DR, Arnold B, Humpierrez J, Schwartz DR, Baker SR, Krause CJ, Swanson N, Carey TE: Serial studies of autologous antibody reactivity to squamous cell carcinoma of the head and neck 329
- Wada S → Ikemoto S
- Walsum M van → Schrijvers AHGJ
- Warter S → Palisson M-J
- Woo D → Adachi K
- Wright SC, Tam AW, Kumar P: Selection of tumor cell variants for resistance to tumor necrosis factor also induces a form of pleiotropic drug resistance 399
- Yajima M → Tsuchiya Y
- Yamakido M, Ishioka S, Hozawa S, Matsuzaka S, Yanagida J, Shigenobu T, Otake M, Nishimoto Y: Effect of *Nocardia rubra* cell-wall skeleton on cancer prevention in humans 389
- Yanagida J → Yamakido M
- Yano O → Kuramoto E
- Yefenof E, Einat E, Klein E: Potentiation of T cell immunity against radiation-leukemia-virus-induced lymphoma by polysaccharide K 133
- Zahn G → Digel W
- Zan-Bar I → Farkas R
- Zeuthen J → Hermann GG